IL13RA2 and glioblastoma: BiCAR-T cells simultaneously expressing HER2 and IL13Rα2 CAR molecules showed higher efficiency in removing glioblastoma tumor cells and lower antigen escape variants than CAR-T cells targeting HER2 alone or pooled CAR-T cells in mouse xenograft models [65].